BeyondSpring Inc.

87 articles with BeyondSpring Inc.

• BeyondSpring to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

  9/11/2020

  - BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on Monday, September 14, 2020, at 1:00 p.m. Eastern Time. The presentation will be

• BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication

  9/8/2020

  Designation Based on PROTECTIVE-2 Phase 3 Interim Data, Reinforcing Significant Treatment Need in CIN

• BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates

  9/3/2020

  Reported Positive Topline Pre-Specified Interim Results from PROTECTIVE-2 (Study 106) Phase 3, Demonstrating Plinabulin’s Superiority in Combination with Neulasta for CIN Prevention vs. Neulasta Alone

• BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Update Conference Call on September 3rd, 2020

  8/27/2020

  BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its second-quarter 2020 financial results and host an operational update conference call on Thursday, September 3 rd , 2020, at 8 a.m. Eastern Time. The conference call may be accessed by dialing 1-877-451-6152 (U.S.) or 1-201-389-0879 (internati

• BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.

  8/11/2020

  - NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients - - First Patient Dosed in the U.S. Avoided Grade 4 Neutropenia in Cycle 2 with Plinabulin and Pegfilgrastim, Despite Experiencing Grade 4 Neutropenia in Cycle 1 with Pegfilgrastim Alone - NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative

• New Stem Cell-Based Application for BeyondSpring’s Plinabulin Presented at ISSCR Annual Meeting

  6/30/2020

  BeyondSpring Inc. announced that the Company presented clinical data on BeyondSpring’s first-in-class, late-stage asset, Plinabulin, showing potent CD34+ progenitor cell mobilization from bone marrow, which has broad applications for stem cell-based therapies, gene therapy and regenerative medicine.

• New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring’s Plinabulin

  6/23/2020

  Research Presented at 2020 AACR Virtual Annual Meeting The Triple I/O Combination of Plinabulin, Anti-PD-1 and Radiation Achieved a 100 Percent Complete Response in Anti-PD-1 Non-responsive Animal Model Triple I/O Combination to Be Administered to Patients Who Failed I/O in Second Half of 2020 NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-

• BeyondSpring Announces Pricing of Ordinary Shares - June 19, 2020

  6/19/2020

  BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced the pricing of its public offering of 1,930,000 ordinary shares at a public offering price of $13.00 per share.

• BeyondSpring Announces Proposed Public Offering of Ordinary Shares - June 18, 2020

  6/18/2020

  BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced the launch of an underwritten public offering of its ordinary shares.

• BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention

  6/15/2020

  BeyondSpring, a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced positive topline results at the pre-specified interim analysis of its PROTECTIVE-2 Phase 3 trial, evaluating Plinabulin in combination with Neulasta versus Neulasta alone.

• BeyondSpring’s PROTECTIVE-2 (Study 106) Phase 2 Trial for Chemotherapy-Induced Neutropenia Shows Positive Results in Chemotherapy Optimization with Potentially Better Clinical Outcomes

  6/9/2020

  Plinabulin in Combination with Neulasta Improves Dose and Regimen Compliance of TAC Chemotherapy Compared to Neulasta Alone

• BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study Without Modification

  6/3/2020

  - DSMB Reviewed Over 500 Patients’ Data in Second Interim Analysis to Assess Overall Benefit / Risk with Plinabulin in Second- and Third-Line, EGFR Wild-Type NSCLC - - Data Continue to Support Plinabulin’s Immune Mechanism-Targeted Patient Selection -

• BeyondSpring E-Poster Presented at 2020 ASCO Virtual Scientific Program

  6/2/2020

  BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abstracts were accepted at this year’s American Society of Clinical Oncology (ASCO) Virtual Scientific Program. Both abstracts evaluate BeyondSpring’s lead late-stage asset, Plinabulin, alongside Neulasta (pegfilgrastim), a long-lasting G-

• BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients

  5/13/2020

  BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent, U.S. 10,596,169, for methods of treating severe chemotherapy-induced neutropenia (CIN) from Taxane in cancer patients by administering its lead asset Plinabulin, wit

• BeyondSpring Reports Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update

  4/30/2020

  FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN

• BeyondSpring Files 2019 Annual Report on Form 20-F

  4/30/2020

  BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019 with the U.S. Securities and Exchange Commission on April 30, 2020.

• FDA Submission to Change the Primary Endpoint into an Industry First and Robust Clinical Measure for Superiority of CIN Phase 3 Study

  4/29/2020

  The Potential for Superior and Rapid Onset Protection from Infection with Plinabulin-G-CSF Combination Marks First Significant Enhancement in Preventing Neutropenia in 30 Years

• CORRECTION – FDA Submission to Change the Primary Endpoint into an Industry First and Robust Clinical Measure for Superiority of CIN Phase 3 Study

  4/29/2020

  The Potential for Superior and Rapid Onset Protection from Infection with Plinabulin-G-CSF Combination Marks First Significant Enhancement in Preventing Neutropenia in 30 Years

• BeyondSpring to Host Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update Conference Call on April 30, 2020

  4/23/2020

  BeyondSpring Inc. announced that the Company will report its fourth-quarter and full-year 2019 financial results and host an operational update conference call on Thursday, April 30, 2020, at 8 a.m. Eastern Time..

• BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia

  3/30/2020

  - Potential to be First Superior Therapy to Standard of Care for Chemotherapy-Induced Neutropenia in 30 Years - - Targeting CIN After All Chemotherapies in All Cancer Types in Combination with All G-CSFs - - Strong Patent Protection Through 2036 - NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company headquartered in New York focused on the development of innovative immuno-oncolog